Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTHFree Report) in a research note issued to investors on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating on the stock.

DNTH has been the topic of a number of other reports. Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average price target of $46.43.

Get Our Latest Research Report on Dianthus Therapeutics

Dianthus Therapeutics Stock Up 3.3 %

Shares of Dianthus Therapeutics stock opened at $23.80 on Friday. The business has a 50-day moving average price of $25.69 and a 200 day moving average price of $26.64. Dianthus Therapeutics has a fifty-two week low of $7.75 and a fifty-two week high of $33.77. The firm has a market cap of $704.48 million, a P/E ratio of -9.52 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTHGet Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities research analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its position in shares of Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock worth $25,936,000 after buying an additional 273,670 shares during the period. State Street Corp raised its stake in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares in the last quarter. Great Point Partners LLC raised its stake in Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after acquiring an additional 132,929 shares in the last quarter. Braidwell LP boosted its position in Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after acquiring an additional 126,836 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after purchasing an additional 263,500 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

See Also

Analyst Recommendations for Dianthus Therapeutics (NASDAQ:DNTH)

Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.